Uno studio per indagare la sicurezza e la tollerabilità del QEQ278 per via endovenosa in pazienti con tumori solidi avanzati
Uno studio di fase I/Ib, in aperto, multicentrico, su QEQ278 in pazienti con tumori solidi avanzati
To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.
In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.
The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
-
Brussels, Belgio, 1200
- Novartis Investigative Site
-
-
-
-
-
Paris, Francia, 75231
- Novartis Investigative Site
-
-
-
-
-
Essen, Germania, 45147
- Novartis Investigative Site
-
-
-
-
Chiba
-
Kashiwa, Chiba, Giappone, 2778577
- Novartis Investigative Site
-
-
-
-
MI
-
Milan, MI, Italia, 20133
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 168583
- Novartis Investigative Site
-
-
-
-
-
Barcelona, Spagna, 08035
- Novartis Investigative Site
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- University of California LA
-
-
Florida
-
Fort Myers, Florida, Stati Uniti, 33901
- Florida Cancer Specialists
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Stati Uniti, 02114
- Massachusetts General Hospital Dept. of Mass General Hospital
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Adult men and women ≥ 18 years of age.
- Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
- In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
- Non-small cell lung cancer
- Esophageal squamous cell carcinoma
- Renal cell carcinoma
- HPV-associated head and neck squamous cell carcinoma
- Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.
Exclusion Criteria:
- Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
- Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
- Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
- Clinically significant cardiac disease or risk factors at screening
- Insufficient bone marrow function at screening:
- Infections:
- Known history of testing positive for Human Immunodeficiency Virus infection.
- Active Hepatitis B and / or Hepatitis C.
- Active, documented COVID-19 infection
- Known history of tuberculosis
- Any serious uncontrolled infection (acute or chronic).
- Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.
Other protocol-defined inclusion/exclusion criteria may apply.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: Dose escalation
Dose escalation with QEQ278 single agent |
Intravenous dosing of QEQ278 |
|
Sperimentale: Part 2: Dose expansion
Dose expansion with QEQ278 single agent |
Intravenous dosing of QEQ278 |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Incidence and nature of Dose Limiting Toxicities (DLTs) during the DLT evaluation period for single agent QEQ278
Lasso di tempo: 28 days
|
A DLT is defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the DLT evaluation period and meets the criteria defined in the study protocol. |
28 days
|
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Lasso di tempo: Up to 31 months
|
Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), including changes in laboratory values, vital signs, and electrocardiograms (ECGs) qualifying and reported as AEs. |
Up to 31 months
|
|
Frequency of dose interruptions, reductions
Lasso di tempo: Up to 30 months
|
Number of dose interruptions of QEQ278 and number of dose reductions of QEQ278 |
Up to 30 months
|
|
Dose intensity
Lasso di tempo: Up to 30 months
|
Dose intensity of QEQ278 is defined as the ratio of actual cumulative dose received and actual duration of exposure. |
Up to 30 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall response rate (ORR) per RECIST v1.1
Lasso di tempo: Up to 30 months
|
ORR is defined as the proportion of patients with a confirmed BOR of complete response (CR) or partial response (PR) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Disease control rate (DCR) per RECIST v1.1
Lasso di tempo: Up to 30 months
|
DCR is defined as the proportion of patients with a confirmed best overall response (BOR) of CR or PR or stable disease (SD) by local investigator review as per RECIST v1.1. |
Up to 30 months
|
|
Duration of Response (DOR) per RECIST v1.1
Lasso di tempo: Up to 30 months
|
DOR is defined as the time form the date of the first documented response (CR or PR) to the date of the first documented progression by local investigator review as per RECIST v1.1 or death due to underlying cancer. |
Up to 30 months
|
|
Progression-free survival (PFS) per RECIST v 1.1
Lasso di tempo: Up to 30 months
|
PFS is defined as the time from the date of start of treatment to the date of the first documented progression by local investigator review as per RECIST v1.1, or death due to any cause. |
Up to 30 months
|
|
Peak serum concentration (Cmax) of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) last of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The AUC from time zero to the last measurable concentration sampling time |
During first 168 days of treatment
|
|
Area under the concentration time curve (AUC) infinity of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The AUC from time zero to infinity |
During first 168 days of treatment
|
|
Time to reach peak serum concentration (Tmax) of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The time to reach maximum (peak) serum drug concentration after single dose administration |
During first 168 days of treatment
|
|
Elimination half-life (T1/2) of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve |
During first 168 days of treatment
|
|
Total body clearance (CL) of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The total body clearance of drug from the serum |
During first 168 days of treatment
|
|
Volume of distribution (Vz) of QEQ278
Lasso di tempo: During first 168 days of treatment
|
The apparent volume of distribution during terminal phase |
During first 168 days of treatment
|
|
Incidence of anti-drug antibody (ADA)
Lasso di tempo: Day 1 and 15
|
Immunogenicity of QEQ278 |
Day 1 and 15
|
Collaboratori e investigatori
Sponsor
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie delle vie respiratorie
- Neoplasie per tipo istologico
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie dell'apparato digerente
- Malattie gastrointestinali
- Malattie polmonari
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Neoplasie delle vie respiratorie
- Neoplasie toraciche
- Malattie esofagee
- Neoplasie polmonari
- Neoplasie urologiche
- Carcinoma
- Neoplasie, cellule squamose
- Neoplasie renali
- Carcinoma, broncogeno
- Neoplasie bronchiali
- Carcinoma, cellule squamose
- Neoplasie esofagee
- Carcinoma a cellule squamose della testa e del collo
- Carcinoma a cellule squamose dell'esofago
- Carcinoma, cellule renali
- Carcinoma, polmone non a piccole cellule
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- CQEQ278A12101
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .